27 Jun, 2023

Unprecedented Reduction in Key Alzheimer’s Biomarker for Patients Treated With ALZ-801

alzheon2023-07-28T10:07:13-04:00June 27th, 2023|

Read More

27 Jun, 2023

A First of Its Kind, ALZ-801 Aims To Preserve Memories, Save Lives: An Exclusive Interview with Dr. Martin Tolar

alzheon2023-07-27T17:26:57-04:00June 27th, 2023|

Read More

27 Jun, 2023

The Science Behind the Drug That May Stop Alzheimer’s Disease in Its Tracks

alzheon2023-07-17T13:26:16-04:00June 27th, 2023|

Read More

10 May, 2023

Understanding Patient Characteristics of Phase 3 APOLLOE4 Trial of ALZ-801 in Alzheimer Disease: John Hey, PhD

alzheon2023-05-31T18:05:53-04:00May 10th, 2023|

Read More

6 May, 2023

Eli Lilly’s Donanemab: The Anti-Amyloid Saga Continues

alzheon2023-07-31T15:59:29-04:00May 6th, 2023|

Read More

28 Apr, 2023

AAN 2023: ALZ-801 for Alzheimer’s found to improve cognition in trial

alzheon2023-05-03T11:24:17-04:00April 28th, 2023|

Read More

28 Apr, 2023

Oral Anti-Amyloid Shows Disease-Modifying Potential: Phase 2 Data

alzheon2023-05-03T12:05:29-04:00April 28th, 2023|

Read More

18 Apr, 2023

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

alzheon2023-04-17T09:08:36-04:00April 18th, 2023|

Read More

22 Mar, 2023

Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden

alzheon2023-03-21T16:07:39-04:00March 22nd, 2023|

Read More

20 Mar, 2023

The New Era of Life Sciences

alzheon2023-03-24T11:32:03-04:00March 20th, 2023|

Read More